Sandra Van Schaeybroeck

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Tyrosine Kinase

Dna Damage Response

Endoplasmic Reticulum Stress

Top Venues

Molecular cancer research : MCR

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Daryl Griffin, Robbie Carson, Deborah Y Moss, Tamas Sessler, Deborah P Lavin, Vijay K Tiwari, Shivaali Karelia, Richard D Kennedy, Kienan I Savage, Simon S McDade, Adam Carie, Jim Pankovich, Mark Bazett, Sandra Van Schaeybroeck
Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. Molecular cancer research : MCR (2024)
Daryl Griffin, Robbie Carson, Deborah Y Moss, Tamas Sessler, Deborah P Lavin, Vijay K Tiwari, Shivaali Karelia, Richard D Kennedy, Kienan I Savage, Simon S McDade, Adam Carie, Jim Pankovich, Mark Bazett, Sandra Van Schaeybroeck
Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. Molecular cancer research : MCR (2024)
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Federica Di Nicolantonio, Simon S McDade, Christopher J Scott, Shauna Lambe, Manisha Maurya, Andreas U Lindner, Jochen H M Prehn, Jose Sousa, Chris Winnington, Melissa J LaBonte, Sarah J Ross, Sandra Van Schaeybroeck
Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. Molecular cancer therapeutics (2022)